CLEVELAND, OH - For a deadly disease with nearly 9 million new cases and 1.6 million deaths worldwide each year, the war on tuberculosis [TB] may get a little boost. Case Western Reserve University School of Medicine is pleased to announce that the Tuberculosis Research Unit (TBRU) at the School of Medicine has received a $27 million / 7 year contract from the National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health, to continue its work in TB research. The TBRU is the only one of its kind supported by the NIH in the United States. The previous award in 1999 was $28 million over seven years. As individual NIH grants are cut across the nation due to a flat federal NIH budget, the significance of the award and its dollar amount are welcome.
The contract will allow researchers to build on a long-standing tradition of multi-disciplinary TB research at the School of Medicine through its international collaborations in Uganda, Brazil, South Africa and Philippines. The Uganda-Case Research Collaboration (UCRC) with colleagues at Makerere University, Mulago Hospital and the Joint Clinical Research Center in Kampala, Uganda, will feature prominently in this new contract. There also will be greatly expanded research activities with investigators at the University of Capetown and the South African TB Vaccine Initiative (SATVI) in Capetown, South Africa. This international consortium of physician and research scientists in two African countries and 10 United States research institutions will conduct studies of the genetics, immunology, microbiology and epidemiology of this often fatal disease in countries where TB is an enormous public health problem.
"Renewal of this research program is a wonderful opportunity to bring together new colleagues in the United States, Uganda and South Africa for TB research focused on understanding how the infection is transmitted and why some people go on to develop active disea
Contact: Susan Licate
Case Western Reserve University